The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial

Transfusion
T H PriceR I Abels

Abstract

This randomized controlled study was undertaken to determine the effect of recombinant human erythropoietin (rHuEPO) on erythropoiesis, autologous blood collection, and allogeneic transfusion risk in elective surgery patients with low baseline hematocrits. Patients (n = 204) with low baseline hematocrits ( < or = 39%), scheduled for orthopedic surgery within 25 to 35 days, were seen every 3 to 4 days for 21 days. At each visit, 450 mL of blood was collected if the hematocrit was > or = 33 percent, and rHuEPO (600 U/kg) or placebo was administered intravenously. One hundred seventy-three patients were evaluable. The number of autologous units collected from the rHuEPO and control groups, respectively, was 4.5 +/- 1.0 and 3.0 +/- 1.1 (p < 0.001), and marrow production of red cells increased by 668 +/- 222 and 353 +/- 155 mL over and above baseline production (p < 0.05). Allogeneic blood transfusion was required by 31 percent of control and 20 percent of rHuEPO patients (p = 0.09). Excluding 8 patients who received > 6 units, 29 percent of control and 14 percent of rHuEPO patients required allogeneic blood (p = 0.015). Logistic regression modeling determined that the risk of allogeneic transfusion was reduced by rHuEPO (p = 0.025)...Continue Reading

Citations

Jun 17, 1999·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·T G Monk
Jun 16, 2004·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Maria J ColominaCarlos Villanueva
Sep 3, 2011·HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery·Kathrin KleinertClément M L Werner
May 27, 2004·Current Oncology Reports·David P Steensma
Jun 2, 2011·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Kanjaksha Ghosh, Kinjalka Ghosh
Feb 6, 1997·Transfusion Science·D H Pamphilon
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B RauW Franke
Mar 3, 1998·Vox Sanguinis·J P AuBuchonE Lee
Mar 27, 1997·The New England Journal of Medicine·L T GoodnoughG L Andriole
Apr 22, 1999·Postgraduate Medical Journal·H I Atrah
Apr 18, 2013·Best Practice & Research. Clinical Anaesthesiology·Michael AuerbachAryeh Shander
Aug 4, 2005·Annals of Hematology·Michael Heuser, Arnold Ganser
Nov 14, 2013·Expert Opinion on Biological Therapy·Diane H D TranMichael G Irwin
Sep 1, 1999·Rheumatic Diseases Clinics of North America·M Shaw, B F Mandell
Aug 20, 2005·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Manuel Vargas-PabonJose Luis Cerra Sabio
Mar 31, 2004·The American Journal of Medicine·Aryeh ShanderRichard Spence
Apr 20, 2001·Journal of Maxillofacial Surgery·Maria ChristopoulouIoannis Iatrou
Dec 5, 2000·Baillière's Best Practice & Research. Clinical Haematology·E C Vamvakas, A A Pineda
Aug 12, 2009·The Medical Clinics of North America·Manish S Patel, Jeffrey L Carson
Jun 1, 2005·Anesthesiology Clinics of North America·E Michael Keating
Feb 28, 2003·Cytokines, Cellular & Molecular Therapy·MaryAnn FooteDavid A Goodkin
Feb 24, 2007·Annals of the Royal College of Surgeons of England·Kelvin K W LauDavid H A Jones
Sep 30, 1998·Journal of Medical Ethics·J Savulescu
Dec 4, 2010·Experimental Biology and Medicine·James W Fisher
Jan 26, 1999·Clinical Orthopaedics and Related Research·L T Goodnough, T G Monk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.